Payment overview · 2025
General Payments
$869.73
43 reported records · 16 companies
Healthcare provider profile · identity verified
Esfandiar Mafi, MD
Allopathic & Osteopathic Physicians|Family Medicine · AMHERST, NY · NPI 1780656447
Verified facts
What the public records show
CMS Open Payments records show Esfandiar Mafi, MD received $869.73 in general payments during 2025 across 43 reported records.
Takeda Pharmaceuticals U.S.A., Inc. accounted for 15.9% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 21 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Jardiance, Mounjaro, Ozempic, Trelegy Ellipta.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYNTHROID as an associated drug or biological on 10655 records involving 4881 distinct recipient NPIs. Public Medicare Part D data also shows 51 claims for Synthroid by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRELEGY ELLIPTA as an associated drug or biological on 131532 records involving 37148 distinct recipient NPIs. Public Medicare Part D data also shows 41 claims for Trelegy Ellipta by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 109 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported MOUNJARO as an associated drug or biological on 186719 records involving 66436 distinct recipient NPIs. Public Medicare Part D data also shows 36 claims for Mounjaro by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRULICITY as an associated drug or biological on 71 records involving 57 distinct recipient NPIs. Public Medicare Part D data also shows 111 claims for Trulicity by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 145 claims for Ozempic by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 37 claims for Eliquis by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported PAXLOVID as an associated drug or biological on 24465 records involving 15715 distinct recipient NPIs. Public Medicare Part D data also shows 20 claims for Paxlovid by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Takeda Pharmaceuticals U.S.A., Inc. | Unresolved — no canonical attribution shown | $138.54 | 15.9% | 7 | 2025 |
| Exact Sciences Corporation | Unresolved — no canonical attribution shown | $114.79 | 13.2% | 7 | 2025 |
| Regeneron Healthcare Solutions, Inc. | Unresolved — no canonical attribution shown | $100.05 | 11.5% | 4 | 2025 |
| Abbott Laboratories | Unresolved — no canonical attribution shown | $68.99 | 7.9% | 3 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $66.37 | 7.6% | 3 | 2025 |
| Madrigal Pharmaceuticals | Unresolved — no canonical attribution shown | $63.64 | 7.3% | 2 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $54.07 | 6.2% | 3 | 2025 |
| Corcept Therapeutics | Unresolved — no canonical attribution shown | $49.74 | 5.7% | 3 | 2025 |
| MOTIVA USA, LLC | Unresolved — no canonical attribution shown | $35.50 | 4.1% | 1 | 2025 |
| Salix Pharmaceuticals, a division of Bausch Health US, LLC | Unresolved — no canonical attribution shown | $33.97 | 3.9% | 2 | 2025 |
| GlaxoSmithKline, LLC. | Unresolved — no canonical attribution shown | $32.25 | 3.7% | 2 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $29.95 | 3.4% | 2 | 2025 |
| SANOFI-AVENTIS U.S. LLC | Unresolved — no canonical attribution shown | $29.41 | 3.4% | 1 | 2025 |
| ABBVIE INC. | Unresolved — no canonical attribution shown | $20.97 | 2.4% | 1 | 2025 |
| Insulet Corporation | Unresolved — no canonical attribution shown | $16.33 | 1.9% | 1 | 2025 |
| Axsome Therapeutics, Inc. | Unresolved — no canonical attribution shown | $15.16 | 1.7% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $869.73 | 43 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| ENTYVIO Normalized: entyvio |
Biological | Takeda Pharmaceuticals U.S.A., Inc. | $138.54 | 7 | 2025 |
Source payment records
|
|||||
| DUPIXENT Normalized: dupixent |
Biological | Regeneron Healthcare Solutions, Inc. | $100.05 | 4 | 2025 |
Source payment records
|
|||||
| The Cologuard Plus Collection Kit Normalized: the cologuard plus collection kit |
Device | Exact Sciences Corporation | $85.24 | 5 | 2025 |
Source payment records
|
|||||
| FREESTYLE LIBRE 3 Normalized: freestyle libre 3 |
Device | Abbott Laboratories | $68.99 | 3 | 2025 |
Source payment records
|
|||||
| REZDIFFRA Normalized: rezdiffra |
Drug | Madrigal Pharmaceuticals | $63.64 | 2 | 2025 |
Source payment records
|
|||||
| Korlym Normalized: korlym |
Drug | Corcept Therapeutics | $49.74 | 3 | 2025 |
Source payment records
|
|||||
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $37.48 | 2 | 2025 |
Source payment records
|
|||||
| Motiva Implant Matrix Normalized: motiva implant matrix |
Device | MOTIVA USA, LLC | $35.50 | 1 | 2025 |
Source payment records
|
|||||
| XIFAXAN Normalized: xifaxan |
Drug | Salix Pharmaceuticals, a division of Bausch Health US, LLC | $33.97 | 2 | 2025 |
Source payment records
|
|||||
| TRELEGY ELLIPTA Normalized: trelegy ellipta |
Drug | GlaxoSmithKline, LLC. | $32.25 | 2 | 2025 |
Source payment records
|
|||||
| Cologuard Collection Kit Normalized: cologuard collection kit |
Device | Exact Sciences Corporation | $29.55 | 2 | 2025 |
Source payment records
|
|||||
| TZIELD Normalized: tzield |
Biological | SANOFI-AVENTIS U.S. LLC | $29.41 | 1 | 2025 |
Source payment records
|
|||||
| Rybelsus Normalized: rybelsus |
Drug | Novo Nordisk Inc | $17.07 | 1 | 2025 |
Source payment records
|
|||||
| MOUNJARO Normalized: mounjaro |
Drug | Lilly USA, LLC | $16.43 | 1 | 2025 |
Source payment records
|
|||||
| ZEPBOUND Normalized: zepbound |
Drug | Lilly USA, LLC | $16.43 | 1 | 2025 |
Source payment records
|
|||||
| Omnipod Normalized: omnipod |
Device | Insulet Corporation | $16.33 | 1 | 2025 |
Source payment records
|
|||||
| Symbravo Normalized: symbravo |
Drug | Axsome Therapeutics, Inc. | $15.16 | 1 | 2025 |
Source payment records
|
|||||
| ABRYSVO Normalized: abrysvo |
Biological | PFIZER INC. | $14.39 | 1 | 2025 |
Source payment records
|
|||||
| COMIRNATY Normalized: comirnaty |
Biological | PFIZER INC. | $14.39 | 1 | 2025 |
Source payment records
|
|||||
| PREVNAR 20 Normalized: prevnar 20 |
Biological | PFIZER INC. | $14.39 | 1 | 2025 |
Source payment records
|
|||||
| JARDIANCE Normalized: jardiance |
Drug | Lilly USA, LLC | $13.52 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| JARDIANCE jardiance |
2025 | Jardiance | 2024 | 109 | exact normalized | Medicare Part D |
| MOUNJARO mounjaro |
2025 | Mounjaro | 2024 | 36 | exact normalized | Medicare Part D |
| Ozempic ozempic |
2025 | Ozempic | 2024 | 145 | exact normalized | Medicare Part D |
| TRELEGY ELLIPTA trelegy ellipta |
2025 | Trelegy Ellipta | 2024 | 41 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | SYNTHROID open payments reported associated product |
CMS Open Payments — General Payments 10655 supporting records · 4881 recipient NPIs · example record 1201352636 |
Synthroid · 2024 Exact normalized brand match · 1 Part D row |
51 | 16 |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | TRELEGY ELLIPTA open payments reported associated product |
CMS Open Payments — General Payments 131532 supporting records · 37148 recipient NPIs · example record 1190332369 |
Trelegy Ellipta · 2024 Exact normalized brand match · 1 Part D row |
41 | suppressed by CMS |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
109 | 22 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | MOUNJARO open payments reported associated product |
CMS Open Payments — General Payments 186719 supporting records · 66436 recipient NPIs · example record 1186464455 |
Mounjaro · 2024 Exact normalized brand match · 1 Part D row |
36 | 12 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | TRULICITY open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 57 recipient NPIs · example record 1186464601 |
Trulicity · 2024 Exact normalized brand match · 1 Part D row |
111 | 15 |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
145 | 24 |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
37 | 18 |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | PAXLOVID open payments reported associated product |
CMS Open Payments — General Payments 24465 supporting records · 15715 recipient NPIs · example record 1228794432 |
Paxlovid · 2024 Exact normalized brand match · 1 Part D row |
20 | 20 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Amlodipine Besylate | Amlodipine Besylate | 478 | 130 |
| Atorvastatin Calcium | Atorvastatin Calcium | 377 | 104 |
| Metoprolol Succinate | Metoprolol Succinate | 340 | 93 |
| Losartan Potassium | Losartan Potassium | 332 | 93 |
| Omeprazole | Omeprazole | 328 | 104 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 322 | 102 |
| Levothyroxine Sodium | Levothyroxine Sodium | 283 | 74 |
| Hydrochlorothiazide | Hydrochlorothiazide | 238 | 65 |
| Pravastatin Sodium | Pravastatin Sodium | 200 | 56 |
| Furosemide | Furosemide | 198 | 63 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 194 | 76 |
| Gabapentin | Gabapentin | 171 | 43 |
| Alprazolam | Alprazolam | 164 | 30 |
| Glipizide Er | Glipizide | 151 | 32 |
| Prednisone | Prednisone | 151 | 101 |
| Ozempic | Semaglutide | 145 | 24 |
| Montelukast Sodium | Montelukast Sodium | 138 | 33 |
| Metformin Hcl Er | Metformin Hcl | 133 | 39 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 127 | 26 |
| Tamsulosin Hcl | Tamsulosin Hcl | 118 | 39 |
| Fluticasone Propionate | Fluticasone Propionate | 116 | 46 |
| Sertraline Hcl | Sertraline Hcl | 113 | 32 |
| Trulicity | Dulaglutide | 111 | 15 |
| Jardiance | Empagliflozin | 109 | 22 |
| Lisinopril | Lisinopril | 107 | 31 |
| Pantoprazole Sodium | Pantoprazole Sodium | 107 | 33 |
| Metformin Hcl | Metformin Hcl | 106 | 30 |
| Escitalopram Oxalate | Escitalopram Oxalate | 104 | 30 |
| Famotidine | Famotidine | 97 | 21 |
| Meloxicam | Meloxicam | 96 | 26 |
| Buspirone Hcl | Buspirone Hcl | 95 | 24 |
| Clonazepam | Clonazepam | 90 | 15 |
| Potassium Chloride | Potassium Chloride | 81 | 18 |
| Azithromycin | Azithromycin | 80 | 65 |
| Allopurinol | Allopurinol | 77 | 24 |
| Mirtazapine | Mirtazapine | 73 | 20 |
| Duloxetine Hcl | Duloxetine Hcl | 72 | 20 |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 72 | 17 |
| Quetiapine Fumarate | Quetiapine Fumarate | 70 | 15 |
| Tramadol Hcl | Tramadol Hcl | 63 | 26 |
| Celecoxib | Celecoxib | 56 | 12 |
| Ibuprofen | Ibuprofen | 53 | 19 |
| Bupropion Xl | Bupropion Hcl | 52 | 17 |
| Amitriptyline Hcl | Amitriptyline Hcl | 51 | suppressed |
| Synthroid | Levothyroxine Sodium | 51 | 16 |
| Trazodone Hcl | Trazodone Hcl | 48 | 15 |
| Atenolol | Atenolol | 46 | 12 |
| Clonidine Hcl | Clonidine Hcl | 46 | 11 |
| Clopidogrel | Clopidogrel Bisulfate | 46 | 13 |
| Symbicort | Budesonide/Formoterol Fumarate | 46 | 12 |
| Pioglitazone Hcl | Pioglitazone Hcl | 44 | 12 |
| Insulin Lispro Kwikpen U-100 | Insulin Lispro | 43 | suppressed |
| Bupropion Hcl Sr | Bupropion Hcl | 42 | 14 |
| Carvedilol | Carvedilol | 42 | 13 |
| Xarelto | Rivaroxaban | 42 | suppressed |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 41 | 11 |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 41 | suppressed |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 40 | 23 |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 40 | 11 |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 39 | 29 |
| Eliquis | Apixaban | 37 | 18 |
| Meclizine Hcl | Meclizine Hcl | 37 | 13 |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 36 | suppressed |
| Mounjaro | Tirzepatide | 36 | 12 |
| Donepezil Hcl | Donepezil Hcl | 33 | 11 |
| Halobetasol Propionate | Halobetasol Propionate | 33 | 18 |
| Irbesartan | Irbesartan | 33 | suppressed |
| Oxybutynin Chloride | Oxybutynin Chloride | 32 | 12 |
| Propranolol Hcl | Propranolol Hcl | 32 | 11 |
| Zolpidem Tartrate | Zolpidem Tartrate | 32 | suppressed |
| Acetaminophen-Codeine | Acetaminophen With Codeine | 31 | 13 |
| Paroxetine Hcl | Paroxetine Hcl | 31 | suppressed |
| Spironolactone | Spironolactone | 31 | 11 |
| Hydralazine Hcl | Hydralazine Hcl | 30 | suppressed |
| Lovastatin | Lovastatin | 30 | suppressed |
| Amoxicillin | Amoxicillin | 27 | 19 |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 27 | 21 |
| Doxycycline Hyclate | Doxycycline Hyclate | 27 | 24 |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 27 | suppressed |
| Valsartan | Valsartan | 27 | suppressed |
| Folic Acid | Folic Acid | 26 | suppressed |
| Benazepril Hcl | Benazepril Hcl | 25 | suppressed |
| Ezetimibe | Ezetimibe | 25 | suppressed |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 25 | 12 |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 25 | suppressed |
| Enalapril Maleate | Enalapril Maleate | 24 | suppressed |
| Finasteride | Finasteride | 24 | suppressed |
| Labetalol Hcl | Labetalol Hcl | 24 | suppressed |
| Metoprolol Tartrate | Metoprolol Tartrate | 24 | suppressed |
| Azelastine Hcl | Azelastine Hcl | 23 | 16 |
| Cephalexin | Cephalexin | 23 | 12 |
| Citalopram Hbr | Citalopram Hydrobromide | 23 | suppressed |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 22 | suppressed |
| Vascepa | Icosapent Ethyl | 22 | suppressed |
| Bisoprolol Fumarate | Bisoprolol Fumarate | 21 | suppressed |
| Myrbetriq | Mirabegron | 21 | suppressed |
| Ketoconazole | Ketoconazole | 20 | suppressed |
| Ondansetron Hcl | Ondansetron Hcl | 20 | 15 |
| Paxlovid | Nirmatrelvir/Ritonavir | 20 | 20 |
| Torsemide | Torsemide | 20 | suppressed |
| Memantine Hcl | Memantine Hcl | 19 | suppressed |
| Simvastatin | Simvastatin | 19 | suppressed |
| Baclofen | Baclofen | 18 | 11 |
| Humalog Kwikpen U-100 | Insulin Lispro | 18 | suppressed |
| Alendronate Sodium | Alendronate Sodium | 17 | suppressed |
| Amlodipine-Valsartan | Amlodipine Besylate/Valsartan | 16 | suppressed |
| Breo Ellipta | Fluticasone/Vilanterol | 16 | suppressed |
| Farxiga | Dapagliflozin Propanediol | 16 | suppressed |
| Glipizide | Glipizide | 16 | suppressed |
| Mupirocin | Mupirocin | 16 | suppressed |
| Cilostazol | Cilostazol | 15 | suppressed |
| Colchicine | Colchicine | 15 | suppressed |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 15 | suppressed |
| Droplet Pen Needle | Pen Needle, Diabetic | 15 | suppressed |
| Neomycin-Polymyxin-Hc | Neomycin/Polymyxin B/Hydrocort | 15 | 15 |
| Ultra-Fine Short Pen Needle | Pen Needle, Diabetic | 15 | suppressed |
| Advair Diskus | Fluticasone Propion/Salmeterol | 14 | suppressed |
| Budesonide-Formoterol Fumarate | Budesonide/Formoterol Fumarate | 14 | suppressed |
| Bumetanide | Bumetanide | 14 | suppressed |
| Diclofenac Sodium | Diclofenac Sodium | 14 | suppressed |
| Omega-3 Acid Ethyl Esters | Omega-3 Acid Ethyl Esters | 14 | suppressed |
| Solifenacin Succinate | Solifenacin Succinate | 14 | suppressed |
| Cefdinir | Cefdinir | 13 | suppressed |
| Fluoxetine Hcl | Fluoxetine Hcl | 13 | suppressed |
| Methimazole | Methimazole | 13 | suppressed |
| Naproxen | Naproxen | 13 | suppressed |
| Nitrofurantoin | Nitrofurantoin Macrocrystal | 13 | suppressed |
| Praluent Pen | Alirocumab | 13 | suppressed |
| Procto-Med Hc | Hydrocortisone | 13 | suppressed |
| Advair Hfa | Fluticasone Propion/Salmeterol | 12 | suppressed |
| Bisoprolol-Hydrochlorothiazide | Bisoprolol/Hydrochlorothiazide | 12 | suppressed |
| Lamotrigine | Lamotrigine | 12 | suppressed |
| Naltrexone Hcl | Naltrexone Hcl | 12 | suppressed |
| Nystatin | Nystatin | 12 | suppressed |
| Ropinirole Hcl | Ropinirole Hcl | 12 | suppressed |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 12 | suppressed |
| Zolpidem Tartrate Er | Zolpidem Tartrate | 12 | suppressed |
| Clonidine | Clonidine | 11 | suppressed |
| Ramipril | Ramipril | 11 | suppressed |
| Warfarin Sodium | Warfarin Sodium | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $869.73 · 43 records | Takeda Pharmaceuticals U.S.A., Inc. | ABRYSVO, COMIRNATY, Cologuard Collection Kit, DUPIXENT, ENTYVIO, FREESTYLE LIBRE 3, JARDIANCE, Korlym, MOUNJARO, Motiva Implant Matrix, Omnipod, Ozempic, PREVNAR 20, REZDIFFRA, Rybelsus, Symbravo, TRELEGY ELLIPTA, TZIELD, The Cologuard Plus Collection Kit, XIFAXAN, ZEPBOUND | 8 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Jardiance play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error